Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 77

Gut Microbiome and Aspirin May Reverse Hormonal Issues

Summary: Researchers found that mutations in the Sox3 gene cause hypopituitarism, a condition where the pituitary gland produces insufficient hormones, leading to growth issues and infertility. In a study on mice, they discovered that Sox3 mutations affect brain cells called NG2 glia, which are essential for hormone production.

Treating the mice with aspirin or altering their gut microbiome restored NG2 glia levels and reversed hypopituitarism. These findings suggest that both aspirin and gut bacteria could be explored as potential treatments for people with Sox3 mutations or other hormone-related disorders.

Genetically engineered bacteria solve computational problems

Researchers have developed a groundbreaking system that uses bacteria to mimic the problem-solving capabilities of artificial neural networks.

Cell-based biocomputing is a novel technique that uses cellular processes to perform computations. Such micron-scale biocomputers could overcome many of the energy, cost and technological limitations of conventional microprocessor-based computers, but the technology is still very much in its infancy. One of the key challenges is the creation of cell-based systems that can solve complex computational problems.

Now a research team from the Saha Institute of Nuclear Physics in India has used genetically modified bacteria to create a cell-based biocomputer with problem-solving capabilities. The researchers created 14 engineered bacterial cells, each of which functioned as a modular and configurable system. They demonstrated that by mixing and matching appropriate modules, the resulting multicellular system could solve nine yes/no computational decision problems and one optimization problem.

The cellular system, described in Nature Chemical Biology, can identify prime numbers, check whether a given letter is a vowel, and even determine the maximum number of pizza or pie slices obtained from a specific number of straight cuts. Here, senior author Sangram Bagh explains the study’s aims and findings.

The Soundtrack of Science

Meet Barbara Di Ventura, an engineer turned synthetic biologist at the University of Freiburg, who explores protein dynamics across cell types. Outside of the laboratory, she moonlights as a musician. Di Ventura harmonizes her passion for art and science in musical abstracts, using a guitar to riff about her latest research, transforming scientific communication into a lively experience.

What inspired you to start creating musical abstracts?

I was inspired by Uri Alon, a systems biologist at the Weizmann Institute of Science, who played the guitar and sang songs about his group’s projects in an entertaining way. Then in 2021, we published a paper on a novel optogenetic tool for controlling gene expression in bacteria, and I had this vision to write a song about it.1 We’re constantly asked to describe our work in new ways despite the numerous figures we produce. To me, writing song lyrics is easier than new text. The song “American Pie” came to mind, and it sounded cool with “Bye-bye, L-arabinose drive,” where L-arabinose is the normal inducer of this system.

Scientists discover ‘pause button’ in human development

In some mammals, the timing of the normally continuous embryonic development can be altered to improve the chances of survival for both the embryo and the mother. This mechanism to temporarily slow development, called embryonic diapause, often happens at the blastocyst stage, just before the embryo implants in the uterus.

During diapause, the embryo remains free-floating and pregnancy is extended. This can be maintained for weeks or months before development is resumed, when conditions are favorable. Although not all mammals use this reproductive strategy, the ability to pause development can be triggered experimentally. Whether human cells can respond to diapause triggers remained an open question.

Now, a study by the labs of Aydan Bulut-Karslıoğlu at the Max Planck Institute for Molecular Genetics in Berlin and Nicolas Rivron at the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences in Vienna, has identified that the that control embryonic diapause also seem to be actionable in human cells.

Cancer breakthrough finally maps how deadly tumors spread through the body

NEW YORK — In a groundbreaking development, scientists have created a revolutionary method to track the spread of cancer throughout the body, potentially paving the way for more effective treatments against this devastating disease. The new technology, developed by researchers at Cold Spring Harbor Laboratory and Weill Cornell Medicine in New York, uses genetic “barcodes” to monitor the movement of individual cancer cells, providing unprecedented insights into the process of metastasis.

CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems. In 2020, the Nobel Prize in Chemistry was awarded to the scientists for the discovery of CRISPR–Cas9 system, a revolutionary genome editing technology that advanced DNA therapeutics. Subsequently, the CRISPR–Cas13 system has emerged as a potential tool to identify and rectify errors in RNA sequences. CRISPR–Cas13 is a novel technology is specifically engineered for virus detection and RNA-targeted therapeutics. The CRISPR RNA (CrRNA) targets specific and non-specific RNA sequences, and Cas13 is an effector protein that undergoes conformational changes and cleaves the target RNA. This RNA-targeting system holds tremendous promise for therapeutics and presents a revolutionary tool in the landscape of molecular biology.

Now, in a recently published BioDesign Research study, a team of researchers led by Professor Yuan Yao from ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, China has elucidated the latest research trends of CRISPR–Cas13 in RNA-targeted therapies. Talking about this paper, which was published online on 6 September 2024, in Volume 6 of the journal, Prof. Yao says, “By focusing on RNA-;the intermediary between DNA and proteins-;CRISPR-Cas13 allows scientists to temporarily manipulate gene expression without inducing permanent changes to the genome. This flexibility makes it a safer option in scenarios where genome stability is critical.”

RNA plays a central role in carrying genetic information from DNA to protein-synthesizing machinery, and also regulates gene expression and participates in numerous cellular processes. Defects in RNA splicing or mutations can lead to a wide variety of diseases, ranging from metabolic disorders to cancer. A point mutation occurs when a single nucleotide is erroneously inserted, deleted, or changed. CRISPR–Cas13 plays a role in identifying and correcting these mutations by employing REPAIR (RNA editing for programmable A-to-I replacement) and RESCUE (RNA editing for specific C-to-U exchange) mechanisms. Explaining the applications of Cas13-based gene editors, Prof. Yao adds, “The mxABE editor, for example, can be used to correct a nonsense mutation linked with Duchenne muscular dystrophy that can be corrected with mxABE. This approach has proved high editing efficiency, restoring dystrophin expression to levels more than 50% of those of the wild type.”

Bacterial ‘flipping’ allows genes to assume different forms

Imagine being one cartwheel away from changing your appearance. One flip, and your brunette locks are platinum blond. That’s not too far from what happens in some prokaryotes, or single-cell organisms, such as bacteria, that undergo something called inversions.

A study led by scientists at Stanford Medicine has shown that inversions, which cause a physical flip of a segment of DNA and change an organism’s genetic identity, can occur within a single gene, challenging a central dogma of biology — that one gene can code for only one protein.

“Bacteria are even cooler than I originally thought, and I’m a microbiologist, so I already thought they were pretty cool,” said Rachael Chanin, PhD, a postdoctoral scholar in hematology. Microbiologists have known for decades that bacteria can flip small sections of their DNA to activate or deactivate genes, Chanin said. To the team’s knowledge, however, those somersaulting pieces have never been found within the confines of a single gene.

George Church lab spawns $75m cell therapy startup

GC Therapeutics’ plug-and-play stem cell programming platform aims to reduce cell therapy development time by up to 100 times.

Cell therapies have revolutionized the treatment of certain disease areas; however, challenges in scaling these therapies…

Cell therapy startup GC Therapeutics (GCTx) has emerged from the lab of renowned geneticist George Church, securing a $65 million Series A funding round that brings the total raised by the company to a cool $75 million. The company is on a mission to enable the next generation of cell therapies through its proprietary TFome platform, which GCTx claims is the first plug-and-play induced pluripotent stem cell (iPSC) cellular programming platform.

Developed by a team of scientists in Professor Church’s lab of at Harvard Medical School and the Wyss Institute, TFome aims to help streamline the complex, error-prone and costly process of cell therapy development by accelerating production and enhancing the quality of cell therapies across a wide range of disease areas. The power of the platform lies in its ability to harness transcription factors, the proteins that regulate gene expression and determine cell fate. By precisely controlling these factors, the platform can guide stem cells to differentiate into any desired cell type in a highly efficient and scalable manner.

Offering a single-step process that enables the efficient differentiation of iPSCs into various functional cell types with over 90% efficiency in just four days, GCTx claims that TFome has the potential to reduce the time associated with cell therapy development by up to 100 times compared with conventional methods, while also improving the potency, efficiency, and quality of the resulting cells. The company aims to leverage the platform to develop off-the-shelf iPSC-based medicines, which can be produced quickly and at a lower cost than current alternatives.